Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -41.10% is 29% below its 5-year average of -31.97%, around the middle of its 5-year range (-67.21%–14.24%).
As of the fiscal period ended Tuesday, June 30, 2026. 32.96% below its 12-month average of -30.91%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -41.10%.
RETURN ON EQUITY (ROE)
-41.10%
RETURN ON EQUITY (ROE) AVG TTM
-30.91%
RETURN ON EQUITY (ROE) AVG 3Y
-39.15%
RETURN ON EQUITY (ROE) AVG 5Y
-31.97%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-32.96%
CURRENT VS 3Y AVG
-4.97%
CURRENT VS 5Y AVG
-28.54%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+2.17%
vs the sector median at left
NewAmsterdam Pharma Company N.V.
Market Cap
$2.57B
Return on Equity (ROE)
-41.10%
TTM Avg
-30.91%
3Y Avg
-39.15%
5Y Avg
-31.97%
Market Cap
$2.57B
Return on Equity (ROE)
0.00%
TTM Avg
2.68%
3Y Avg
1.94%
5Y Avg
-2.51%
Market Cap
$2.58B
Return on Equity (ROE)
-8.00%
TTM Avg
-28.91%
3Y Avg
-27.68%
5Y Avg
-39.13%
Market Cap
$2.59B
Return on Equity (ROE)
-0.38%
TTM Avg
-26.55%
3Y Avg
-13.53%
5Y Avg
-6.91%
Market Cap
$2.67B
Return on Equity (ROE)
95.64%
TTM Avg
115.72%
3Y Avg
76.74%
5Y Avg
3213.80%
Market Cap
$2.47B
Return on Equity (ROE)
-10.66%
TTM Avg
1.75%
3Y Avg
2.62%
5Y Avg
5.68%
Market Cap
$2.69B
Return on Equity (ROE)
-56.91%
TTM Avg
-24.13%
3Y Avg
-9.83%
5Y Avg
-11.19%
Market Cap
$2.69B
Return on Equity (ROE)
-25.47%
TTM Avg
-23.80%
3Y Avg
14.67%
5Y Avg
14.67%
Market Cap
$2.69B
Return on Equity (ROE)
-361.91%
TTM Avg
-763.19%
3Y Avg
-396.22%
5Y Avg
-320.76%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NewAmsterdam Pharma Company N.V. (NAMS) | $2.57B | -41.10% | -30.91% | -39.15% | -31.97% |
| Privia Health Group, Inc. (PRVA)vs › | $2.57B | 0.00% | 2.68% | 1.94% | -2.51% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.58B | -8.00% | -28.91% | -27.68% | -39.13% |
| Neogen Corporation (NEOG)vs › | $2.59B | -0.38% | -26.55% | -13.53% | -6.91% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.67B | 95.64% | 115.72% | 76.74% | 3213.80% |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.47B | -10.66% | 1.75% | 2.62% | 5.68% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | -56.91% | -24.13% | -9.83% | -11.19% |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.69B | -25.47% | -23.80% | 14.67% | 14.67% |
| Precigen, Inc. (PGEN)vs › | $2.69B | -361.91% | -763.19% | -396.22% | -320.76% |
| AtriCure, Inc. (ATRC)vs › | $2.73B | 2.04% | -6.01% | -7.18% | -5.00% |
ROE
-41.1%
ROA
-36.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -41.10% |
| 2026-03-31 | -31.98% |
| 2025-12-31 | -29.82% |
| 2025-09-30 | -30.36% |
| 2025-06-30 | -21.29% |
| 2025-03-31 | -24.10% |
| 2024-12-31 | -31.89% |
| 2024-09-30 | -52.50% |
| 2024-06-30 | -59.21% |
| 2024-03-31 | -55.53% |
| 2023-12-31 | -61.35% |
| 2023-09-30 | -35.90% |
| 2023-06-30 | -33.93% |
| 2023-03-31 | -20.82% |
| 2022-12-31 | -4.04% |
| 2022-09-30 | 0.12% |
| 2022-06-30 | 14.24% |
| 2022-03-31 | -1.15% |
| 2021-12-31 | -67.21% |
| 2021-09-30 | -31.02% |
| 2021-06-30 | -6.40% |
| 2021-03-31 | -6.44% |
| 2020-12-31 | -3.35% |
